NI200900179A - Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2. - Google Patents

Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2.

Info

Publication number
NI200900179A
NI200900179A NI200900179A NI200900179A NI200900179A NI 200900179 A NI200900179 A NI 200900179A NI 200900179 A NI200900179 A NI 200900179A NI 200900179 A NI200900179 A NI 200900179A NI 200900179 A NI200900179 A NI 200900179A
Authority
NI
Nicaragua
Prior art keywords
dopamine
pirimidinil
receptor ligands
piperazines useful
same
Prior art date
Application number
NI200900179A
Other languages
English (en)
Inventor
Bartáné Szalai Gizella
Ágainé Csongor Éva
Domány György
Gyertyán István
Kiss Béla
Laszy Judit
Sághy Katalin
Schmidt éva
Farkas Sándor
Komlódi Zsolt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of NI200900179A publication Critical patent/NI200900179A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00—Asymmetric syntheses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con nuevos ligandos de dopamina D3 y D2 de fórmula (I): en donde R1, R2 y Q son como se describe aquí, y/o isómeros geométricos y/o esteroisómeros y/o diastereómeros y/o sales y/o hidratos y/o solvatos y/o polimorfos de los mismos. La invención también se relaciona con procesos para preparar los mismos, con composiciones que contienen los mismos y con su uso en el tratamiento y/o prevención de afecciones que requieren modulación de receptores de dopamina.
NI200900179A 2007-04-11 2009-10-07 Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2. NI200900179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use

Publications (1)

Publication Number Publication Date
NI200900179A true NI200900179A (es) 2010-06-30

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
NI200900179A NI200900179A (es) 2007-04-11 2009-10-07 Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2.

Country Status (36)

Country Link
EP (1) EP2132185B1 (es)
JP (1) JP4580464B2 (es)
KR (1) KR101540821B1 (es)
CN (1) CN101652351B (es)
AP (1) AP2460A (es)
AT (1) ATE518843T1 (es)
AU (1) AU2008237696B2 (es)
BR (1) BRPI0809641A2 (es)
CA (1) CA2682817C (es)
CO (1) CO6241116A2 (es)
CR (1) CR11071A (es)
CU (1) CU23853B1 (es)
CY (1) CY1111962T1 (es)
DK (1) DK2132185T3 (es)
EA (1) EA016174B1 (es)
EC (1) ECSP099702A (es)
ES (1) ES2370748T3 (es)
GE (1) GEP20115272B (es)
HK (1) HK1134491A1 (es)
HR (1) HRP20110785T8 (es)
HU (1) HUP0700269A2 (es)
IL (1) IL200801A0 (es)
MA (1) MA31359B1 (es)
MX (1) MX2009010896A (es)
MY (1) MY148384A (es)
NI (1) NI200900179A (es)
NZ (1) NZ579754A (es)
PL (1) PL2132185T3 (es)
PT (1) PT2132185E (es)
RS (1) RS51979B (es)
SI (1) SI2132185T1 (es)
TN (1) TN2009000386A1 (es)
TW (1) TWI445534B (es)
UA (1) UA103748C2 (es)
WO (1) WO2008125891A2 (es)
ZA (1) ZA200906543B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
LT2582701T (lt) 2010-06-18 2017-03-27 Altos Therapeutics, LLC D2 antagonistai, sintezės būdai ir panaudojimo būdai
US9376396B2 (en) 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
CN111801330B (zh) 2018-01-26 2024-04-05 盐野义制药株式会社 具有多巴胺d3受体拮抗作用的稠环化合物
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) * 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Also Published As

Publication number Publication date
JP4580464B2 (ja) 2010-11-10
BRPI0809641A2 (pt) 2014-11-11
WO2008125891A2 (en) 2008-10-23
HRP20110785T8 (en) 2012-04-30
PT2132185E (pt) 2011-11-21
CN101652351B (zh) 2012-07-04
EA016174B1 (ru) 2012-02-28
SI2132185T1 (sl) 2011-11-30
HK1134491A1 (en) 2010-04-30
CU23853B1 (es) 2012-10-15
MY148384A (en) 2013-04-15
IL200801A0 (en) 2010-05-17
UA103748C2 (uk) 2013-11-25
KR20100082713A (ko) 2010-07-19
CA2682817C (en) 2015-11-24
HUP0700269A2 (en) 2009-04-28
CN101652351A (zh) 2010-02-17
MX2009010896A (es) 2009-12-14
AP2009004970A0 (en) 2009-10-31
CO6241116A2 (es) 2011-01-20
MA31359B1 (fr) 2010-05-03
ZA200906543B (en) 2010-06-30
NZ579754A (en) 2011-11-25
RS51979B (en) 2012-02-29
TN2009000386A1 (en) 2010-12-31
JP2010523642A (ja) 2010-07-15
HU0700269D0 (en) 2007-05-29
GEP20115272B (en) 2011-08-25
TWI445534B (zh) 2014-07-21
AP2460A (en) 2012-09-13
AU2008237696A1 (en) 2008-10-23
WO2008125891A3 (en) 2009-01-08
AU2008237696B2 (en) 2013-03-14
ATE518843T1 (de) 2011-08-15
CY1111962T1 (el) 2015-11-04
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
CU20090161A7 (es) 2011-09-21
TW201002328A (en) 2010-01-16
KR101540821B1 (ko) 2015-07-30
ECSP099702A (es) 2009-11-30
ES2370748T3 (es) 2011-12-22
CA2682817A1 (en) 2008-10-23
EP2132185A2 (en) 2009-12-16
PL2132185T3 (pl) 2011-12-30
DK2132185T3 (da) 2011-10-03
EP2132185B1 (en) 2011-08-03
HRP20110785T1 (hr) 2011-11-30

Similar Documents

Publication Publication Date Title
NI200900179A (es) Pirimidinil - piperazinas útiles como ligandos receptores de dopamina d3/d2.
UY36907A (es) Nuevas carboxamidas de acción microbiocida
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
UY32996A (es) Antagonistas del receptor crth2 basados en indol
CU20110052A7 (es) Compuestos orgánicos
PA8809001A1 (es) Compuestos organicos
CL2011001967A1 (es) Compuestos derivados de carboxamida-azaheterociclica sustituida, inhibidores de p70s6k, proceso de preparacion de estos; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias y cancer; kit farmaceutico.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
CU20090133A7 (es) Compuestos tricíclicos y sus composiciones
ECSP11011206A (es) Nuevos herbicidas.
ECSP11011244A (es) Nuevos herbicidas.
UY33238A (es) "Compuestos en calidad de antagonistas de bradiquinina-b1"
UY30146A1 (es) Radioligandos novedosos
ECSP11011133A (es) Nuevos herbicidas.
ECSP13012600A (es) CO-cristales y Sales de Inhibidores de CCR3
CR11098A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de p13k-alfa para el tratamiento del cancer
CO6341625A2 (es) Derivados de indol como agentes anticáncer
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CO6640201A2 (es) Moduladores de crth2
CU20130065A7 (es) Derivados de indol
CU20110020A7 (es) Compuestos de fenantrenona, composiciones y métodos
AR073708A1 (es) Compuestos intermediarios de tiazolil -pirazolopirimidina y procesos sinteticos que los incluyen
CU20080116A7 (es) 3-aminociclopentanocarboxamidas como muduladores de receptores de quimioquinas